Subcutaneous Infusion

The FDA has approved Vyalev, a continuous, subcutaneous 24-hour infusion, to address motor fluctuations in adults with advanced Parkinson's disease, according to the manufacturer.

Compared with oral administration, continuous subcutaneous infusion of carbidopa/levodopa was linked to nearly 2 more hours of “on” time without dyskinesia in adults with Parkinson’s disease, data from The Lancet Neurology show.

The FDA has approved Rystiggo, a subcutaneous infusion therapy to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.

Despite the benefits and accessibility of administering cancer medications and fluids subcutaneously vs. intravenously, U.S. facilities appear to underuse this delivery method, according to a research letter published in JAMA Oncology.

SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Continuous subcutaneous foslevodopa-foscarbidopa improved motor symptoms and reduced motor fluctuations compared with oral levodopa-carbidopa in patients with advanced Parkinson’s disease, according to a study in The Lancet Neurology.

Subcutaneous insulin therapy was associated with shorter hospital stay and lower cost vs. intravenous insulin infusion for the treatment of mild diabetic ketoacidosis for children with type 1 diabetes, according to study data.

Continuous subcutaneous infusion of foslevodopa/foscarbidopa was safe and improved motor complications in patients with advanced Parkinson’s disease, according to data presented at the European Academy of Neurology Congress 2022.